

Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-244US1	Application No. 10/069,215
	Applicant Stephen Thom et al.		
	Filing Date February 22, 2002	Group Art Unit 1614	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED
 JAN 24 2003
 TECH CENTER 1600/2900


Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AL							
<i>SP</i>	AM	WO 99/37619 A1	29 July 1999 <i>D1</i>	PCT 1	—	—	Original in English	—
<i>SP</i>	AN	WO 99/04794 A1	4 February 1999 <i>D2</i>	PCT 2	—	—	Original in English	—
<i>SP</i>	AO	WO 98/02151 A2	22 January 1998 <i>D3</i>	PCT 3	—	—	Original in English	—
<i>SP</i>	AP	EP 0 903 349 A2	24 March 1999 <i>D4</i>	Europe 4	—	—	Original in English	—
<i>SP</i>	AQ	WO 97/10207	20 March 1997	PCT 5	—	—	—	Original in Japanese
<i>SP</i>	AR	WO 97/19060 A1	29 May 1997	PCT 6	—	—	Original in English	—
<i>SP</i>	AS	WO 98/31364	23 July 1998	PCT 7	—	—	Original in English	—
<i>SP</i>	AT	WO 00/53600	14 September 2000	PCT 8	—	—	—	Original in Japanese

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2
 RECEIVED
 TECH CENTER 1600/2900
 JAN 24 2003



Substitute Form PTO-1449 (modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-244US1	Application No. 10/069,215
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Stephen Thom et al.	
		Filing Date February 22, 2002	Group Art Unit 1614

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>gpc</i>	AU	JP 63-264525	1 November 1 1988	Japan 9	—	—	ABSTRACT ONLY	Original in Japanese

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
<i>gpc</i>	AV	Craig Gerard, "Chemokine Receptors and Ligand Specificity: Understanding the Enigma" Vol. 13, No. 72 (C-570), 21-31, February 17, 1999. 13
<i>gpc</i>	AW	Patent Abstracts of Japan, Medicine Composition Containing Piperazine Derivative and Having Active Oxygen Production Inhibiting And Active Oxygen Removing Action" (November 1, 1988). 11
<i>gpc</i>	AX	Derwent Abstract 2000-587420/55, (2003), corresponding to Foreign Patent Document WO 00/53600, published September 14, 2000 (Reference AT above). 12
<i>gpc</i>	AY	Derwent Abstract 97-212513/19, (2003), corresponding to Foreign Patent Document WO 97/10207 A1, published March 20, 1997 (Reference AQ above). 15
<i>gpc</i>	AZ	Derwent Abstract 98-351249/49, (2003), corresponding to Foreign Patent Document JP 63-264525, published 1 November 1988 (Reference AU above). 14
<i>gpc</i>	AAA	J. Hesselgesser et al., Journal of Biological Chemistry, vol. 273, no. 25, "Identification and Characterisation of Small Molecule Functional Antagonist of the CCR1 Chemokine Receptor" 15687-15692, (1998). 15
<i>gpc</i>	ABB	Howard P. Ng et al., Journal of Medicinal Chemistry, vol. 42, "Discovery of Novel Non-Peptide CCR1 Receptor Antagonists" 4680-4694, (1999). 16
<i>gpc</i>	ACC	Xavier Emodns-Alt et al., "Bioorganic & Medicinal Chemistry Letters, vol. 3, no. 5, "Pharmacological Profile and Chemical Synthesis of SR 48968, a Non-Peptide Antagonist of the Neurokinin A (NK ₂) Receptor" 925-930, (1993). 17

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.